Rezolute, Inc. (RZLT) Market Cap
Rezolute, Inc. has a market capitalization of $454.5M.
Price: $4.72
▼ -0.16 (-3.28%)
Market Cap: 454.50M
NASDAQ · time unavailable
CEO: Nevan Charles Elam
Sector: Healthcare
Industry: Biotechnology
IPO Date: 2013-01-14
Website: https://www.rezolutebio.com
Rezolute, Inc. (RZLT) - Company Information
Market Cap: 454.50M|Sector: Healthcare
Company Profile
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Analyst Sentiment
From 10 Active Polls
1Y Forecast: $8.67
▲ +83.7% Potential Upside
Consensus Target Metrics
Low Bound
$6
Median
$6
High Bound
$14
Average
$9
Price & Moving Averages
🎯 Wall Street Analyst Intelligence Report
1-Year structural target targets, chart projections, and sentiment maps.
Consensus Trend Projection
Trailing closures vs. 12-month metrics map.
Analyst Vote Distribution
Aggregate institutional coverage sentiment weights.
📊 Historical Valuation Multiples
Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.
| Fiscal Quarter | TTM | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Period Ending | Trailing 12M | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 |
| Market Cap ($M) | 454 | 317 | 245 | 972 | 421 | 203 | 343 | 338 | 219 |
| Enterprise Value ($M) | 444 | 307 | 234 | 965 | 328 | 190 | 336 | 330 | 151 |
| Price to Earnings Ratio (P/E) | -5.76 | -4.77 | -2.68 | -13.06 | -4.29 | -2.69 | -5.57 | -5.51 | -2.39 |
| Price/Earnings-to-Growth Ratio (PEG) | — | — | — | — | — | — | — | — | — |
| Price to Sales Ratio (P/S) | — | — | — | — | — | — | — | — | — |
| Price to Book Ratio (P/B) | 4.20 | 2.72 | 1.91 | 6.61 | 2.60 | 2.46 | 3.44 | 2.98 | 1.81 |
| Price to Free Cash Flow Ratio (P/FCF) | -6.19 | -23.10 | -12.04 | -55.78 | -19.13 | -11.67 | -25.08 | -21.12 | -11.82 |
| Enterprise Value to Sales (EV/Sales) | — | — | — | — | — | — | — | — | — |
| Enterprise Value to EBITDA (EV/EBITDA) | -5.46 | -19.01 | -10.28 | -53.17 | -13.46 | -10.06 | -21.35 | -21.46 | -6.57 |
| Debt to Equity Ratio | 0.12 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 |
📰 Market News & Coverage
15 Stories AvailableReal-time institutional reporting and market updates for RZLT.
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
REDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 28-29, 2026.
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
Presentations included analyses of natural history and adverse outcomes in congenital hyperinsulinism (HI), as well as previously reported results from the Company's Phase 3 sunRIZE study in congenital HI and a case series from its Expanded Access Program (EAP) in tumor HI REDWOOD CITY, Calif., June 17, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today highlighted four data presentations delivered at the Annual Meeting of the Endocrine Society (ENDO).
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?
Rezolute rises 38% in a week after interim upLIFT data shows most tumor HI patients cut or eliminate IV glucose support.
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
REDWOOD CITY, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today announced four presentations at the upcoming Annual Meeting of the Endocrine Society (ENDO) being held June 13-16, 2026, in Chicago, IL.
Rezolute Highlights Strong Early Response Trends In Rare Hypoglycemia Disease Study
Rezolute, Inc. (NASDAQ:RZLT) reported an interim update from its ongoing Phase 3 upLIFT study evaluating ersodetug in patients with tumor hyperinsulinism (HI), saying six of the eight participants enrolled so far achieved the study's primary endpoint.
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Study now 50% enrolled 6 of 8 participants have already met the responder criterion for the study's primary endpoint Topline results for the fully enrolled open-label study are expected in the second half of 2026 REDWOOD CITY, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a congenital or any acquired form of hyperinsulinism (HI), today provided an interim update on its ongoing open-label Phase 3 study (upLIFT) of ersodetug in tumor HI.
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
REDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended March 31, 2026.
Rezolute to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced that management will participate in the following investor conferences:
Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
Includes results from additional continuous glucose monitoring (CGM)-based outcomes which demonstrate significant and consistent improvements in glycemic control in ersodetug treatment arms compared to placebo, across multiple pre-specified and post-hoc endpoints
Rezolute, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, April 24, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Rezolute, Inc., (“Rezolute" or the "Company") (NASDAQ: RZLT) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors.
Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting
Oral presentation will include previously announced topline results as well as pre-specified and post-hoc data updates
Rezolute Stock Gains After FDA Meeting on Ersodetug Program Update
RZLT stock jumps 12% after an FDA meeting highlights ersodetug data and next steps, despite an earlier phase III setback in the congenital HI study.
FDA Review Puts Rezolute's Genetic Disorder Drug Path In Question
In a recent update, Rezolute shared insights from its March 17 meeting with the FDA regarding its Phase 3 sunRIZE trial for ersodetug, aimed at treating congenital hyperinsulinism.
Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
REDWOOD CITY, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today announced outcomes from an in-person Type B meeting with the U.S. Food and Drug Administration (FDA) held on March 17, 2026, related to sunRIZE, a Phase 3, multicenter, double-blind, randomized, placebo-controlled safety and efficacy study of ersodetug for the treatment of congenital HI.
Reviewing Rezolute (NASDAQ:RZLT) & ADMA Biologics (NASDAQ:ADMA)
ADMA Biologics (NASDAQ: ADMA - Get Free Report) and Rezolute (NASDAQ: RZLT - Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, risk and earnings. Profitability This table compares ADMA Biologics and Rezolute's net
Related Companies in Healthcare
AURA BIOSCIENCES INC (AURA)
Healthcare
$0.45B
Mkt Cap
CLEARPOINT NEURO INC (CLPT)
Healthcare
$0.45B
Mkt Cap
VIEMED HEALTHCARE INC (VMD)
Healthcare
$0.45B
Mkt Cap
AQUESTIVE THERAPEUTICS INC (AQST)
Healthcare
$0.46B
Mkt Cap
NATIONAL RESEARCH CORP (NRC)
Healthcare
$0.44B
Mkt Cap
NEUROPACE INC (NPCE)
Healthcare
$0.44B
Mkt Cap
📊 AI Financial Analysis
Powered by StockMarketInfo"RZLT reported a pre-revenue quarter: Revenue was $0 and net income was -$16.17M (EPS -$0.16) in 2026-03-31. YoY net income improved (loss narrowed) versus 2025-03-31 (-$18.91M), a ~14.4% reduction in the loss. QoQ, the loss also narrowed versus 2025-12-31 (-$22.77M), an ~29.0% improvement. Operating results show continued cost pressure: R&D was -$11.41M and G&A was -$5.95M, but operating income improved to +$1.20M, driven by a large offset in other income/expense lines (total other income/expenses net of -$17.37M). Over the four-quarter period, profitability remains negative at the bottom line (net losses persist), with EPS losses easing sequentially from the most severe period. Cash flow quality is the key signal right now. Operating cash flow was -$13.74M and free cash flow was -$13.74M. The company continues investing heavily in maturities/purchases of investments, keeping ending cash relatively stable at $11.24M. With no dividends and no buybacks in the quarter, shareholder return is dominated by price action: the stock is up 31.06% over the last year and 59.45% YTD, indicating strong capital appreciation despite persistent operating losses."
Revenue Growth
Revenue was $0 in the most recent quarter and in all comparison periods provided; YoY/QoQ growth is not meaningful.
Profitability
Net income loss narrowed YoY by ~14.4% (-$16.17M vs -$18.91M) and improved QoQ by ~29.0% (-$16.17M vs -$22.77M). However, the company remains loss-making with EPS -$0.16.
Cash Flow Quality
Operating cash flow was -$13.74M and free cash flow -$13.74M. No dividends or buybacks; cash stability appears driven by investment activity rather than operating profitability.
Leverage & Balance Sheet
Balance sheet shows strong liquidity: cash + short-term investments were ~$120.27M. Total assets were $125.46M vs $138.63M QoQ; equity remains sizable at $116.83M, suggesting resilience.
Shareholder Returns
Share price appreciation is strong: +31.06% over 1Y and +59.45% YTD. No dividend yield and no buybacks in the quarter, so total return is primarily price-driven.
Analyst Sentiment & Valuation
Price is $3.46 vs consensus target $6.33 (upside implied), but wide target range ($2–$20) indicates uncertainty typical for pre-commercial/pre-revenue names.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
Fundamentals Overview
📋 Official Regulatory 10-K / 10-Q SEC Filings
Direct authenticated documentation links to audited SEC database reports for RZLT.